Furthermore, YM155 [40], a selective BIRC5 inhibitor, has been found to possess potent antitumor activities against numerous cancers including DLBCL xenografts [41,42] and can determine objective responses in some DLBCL patients as a single agent [43]. The gene discussed is BIRC5; the disease is diffuse large B-cell lymphoma.